CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)

被引：0

作者：

Popat, Rakesh ^{[1
]}

Wilson, William ^{[2
]}

Camilleri, Marquita ^{[2
,3
]}

De Tute, Ruth

Pang, Gavin ^{[2
]}

Jenner, Richard ^{[2
]}

Dadaga, Tushhar ^{[2
]}

Kamora, Sumaiya ^{[2
]}

Streetly, Matthew ^{[4
]}

Ramasamy, Karthik ^{[5
]}

Phillips, Elizabeth ^{[6
]}

Chapman, Mike ^{[7
]}

Bygrave, Ceri ^{[8
]}

Cavenagh, James ^{[9
]}

Sive, Jonathan ^{[2
,10
]}

Benjamin, Reuben

Eccersley, Lydia ^{[9
]}

Hassan, Sandra ^{[11
]}

Willis, Fenella ^{[12
]}

Clifton-Hadley, Laura ^{[13
]}

Owen, Roger ^{[14
]}

Yong, Kwee ^{[2
]}

机构：

[1] Univ Coll London Hosp NHS Fdn Trust, London, England

[2] UCL, Canc Res UK & UCL Canc Trials Ctr, London, England

[3] St James Hosp Leeds, HMDS, Leeds, W Yorkshire, England

[4] Guys & St Thomas NHS Trust, Leeds, W Yorkshire, England

[5] Univ Oxford, Hosp NHS Trust, Oxford, England

[6] Christie NHS Fdn Trust, Manchester, Lancs, England

[7] Cambridge Inst Med Res, Cambridge, England

[8] Univ Hosp Wales, London, England

[9] Barts Hlth NHS Trust, London, England

[10] Kings Coll Hosp London, London, England

[11] Queens Hosp, London, England

[12] St Georges NHS Trust, London, England

[13] UCL, Canc Res UK & UCL Canc Trials Ctr, London, England

[14] St James Inst Oncol, London, England

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-003

引用

页码：S2 / S3

页数：2

共 50 条

[21] A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard- Risk Patients [J].

Gay, Francesca Maria ;

Scalabrini, Delia Rota ;

Belotti, Angelo ;

Galli, Monica ;

Zamagni, Elena ;

Offidani, Massimo ;

Oliva, Stefania ;

Montefusco, Vittorio ;

Zambello, Renato ;

Ledda, Antonio ;

Grasso, Mariella ;

Aquino, Sara ;

Esma, Fabrizio ;

Tosi, Patrizia ;

Pisani, Francesco ;

Annibali, Ombretta ;

Liberati, Anna Marina ;

Baraldi, Anna ;

Galieni, Piero ;

Specchia, Giorgina ;

Pescosta, Norbert ;

Mancuso, Katia ;

Paris, Laura ;

Ribolla, Rossella ;

Coha, Valentina ;

Palumbo, Antonio ;

Musto, Pellegrino ;

Cavo, Michele ;

Boccadoro, Mario .

BLOOD, 2017, 130

[22] Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate [J].

Sonneveld, Pieter ;

Asselbergs, Emilie ;

Zweegman, Sonja ;

Van der Holt, Bronno ;

Kersten, Marie Jose ;

Vellenga, Edo ;

van Marwijk-Kooy, Marinus ;

de Weerdt, Okke ;

Lonergan, Sarah ;

Lokhorst, Henk .

BLOOD, 2012, 120 (21)

[23] Carfilzomib (CFZ, Kyprolis®), Lenalidomide (LEN, Revlimide®), and Dexamethasone (DEX) (KRd) Combined with Autologous Stem Cell Transplant (ASCT) Shows Improved Efficacy Compared with Krd without ASCT in Newly Diagnosed Multiple Myeloma (NDMM) [J].

Zimmerman, Todd M. ;

Griffith, Kent ;

Jasielec, Jagoda K. ;

Rosenbaum, Cara A. ;

Berdeja, Jesus G. ;

Vij, Ravi ;

Raje, Noopur ;

Reece, Donna E. ;

Vesole, David H. ;

Jagannath, Sundar ;

Kaminski, Mark ;

Cole, Craig ;

Nam, Jennifer ;

Stephens, Leonor A. ;

Rosebeck, Shaun ;

Gurbuxani, Sandeep ;

Dytfeld, Dominik ;

Jakubowiak, Andrzej J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) :S40-S40

[24] MAINTENANCE THERAPY WITH LENALIDOMIDE, DEXAMETHASONE AND CLARITHROMYCIN (BIRD) FOLLOWING AUTOLOGOUS TRANSPLANT (ASCT) FOR MULTIPLE MYELOMA (MM) [J].

Holmberg, L. ;

Gooley, T. ;

Becker, P. ;

Bensinger, W. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) :S251-S252

[25] Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial [J].

Gay, Francesca ;

Musto, Pellegrino ;

Rota-Scalabrini, Delia ;

Bertamini, Luca ;

Belotti, Angelo ;

Galli, Monica ;

Offidani, Massimo ;

Zamagni, Elena ;

Ledda, Antonio ;

Grasso, Mariella ;

Ballanti, Stelvio ;

Spadano, Antonio ;

Cea, Michele ;

Patriarca, Francesca ;

D'Agostino, Mattia ;

Capra, Andrea ;

Giuliani, Nicola ;

de Fabritiis, Paolo ;

Aquino, Sara ;

Palmas, Angelo ;

Gamberi, Barbara ;

Zambello, Renato ;

Petrucci, Maria Teresa ;

Corradini, Paolo ;

Cavo, Michele ;

Boccadoro, Mario .

LANCET ONCOLOGY, 2021, 22 (12) :1705-1720

[26] Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma [J].

Sonneveld, Pieter ;

Asselbergs, Emilie ;

Zweegman, Sonja ;

van der Holt, Bronno ;

Kersten, Marie Jose ;

Vellenga, Edo ;

van Marwijk-Kooy, Marinus ;

Broyl, Annemiek ;

de Weerdt, Okke ;

Lonergan, Sarah ;

Palumbo, Antonio ;

Lokhorstl, Henk .

BLOOD, 2015, 125 (03) :449-456

[27] Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma [J].

Bringhen, S. ;

D'Agostino, M. ;

De Paoli, L. ;

Montefusco, V. ;

Liberati, A. M. ;

Galieni, P. ;

Grammatico, S. ;

Muccio, V. E. ;

Esma, F. ;

De Angelis, C. ;

Musto, P. ;

Ballanti, S. ;

Offidani, M. ;

Petrucci, M. T. ;

Gaidano, G. ;

Corradini, P. ;

Palumbo, A. ;

Sonneveld, P. ;

Boccadoro, M. .

LEUKEMIA, 2018, 32 (04) :979-985

[28] Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma [J].

S Bringhen ;

M D'Agostino ;

L De Paoli ;

V Montefusco ;

A M Liberati ;

P Galieni ;

S Grammatico ;

V E Muccio ;

F Esma ;

C De Angelis ;

P Musto ;

S Ballanti ;

M Offidani ;

M T Petrucci ;

G Gaidano ;

P Corradini ;

A Palumbo ;

P Sonneveld ;

M Boccadoro .

Leukemia, 2018, 32 :979-985

[29] Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study [J].

Yong, Kwee ;

Popat, Rakesh ;

Wilson, William ;

Pang, Gavin ;

Jenner, Richard ;

De Tute, Ruth M. ;

Ramasamy, Karthik ;

Streetly, Matthew ;

Cavenagh, Jamie ;

Sive, Jonathan ;

Chapman, Michael ;

Bygrave, Ceri ;

Phillips, Beth ;

Chavda, Selina J. ;

Virchis, Andres E. ;

Benjamin, Reuben ;

Arnott, Sarah ;

Willis, Fenella ;

Hassan, Sandra ;

Moore, Sally ;

Clifton-Hadley, Laura ;

Owen, Roger G. .

BLOOD, 2019, 134

[30] Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). [J].

Zimmerman, Todd M. ;

Griffith, Kent A. ;

Jasielec, Jagoda ;

Rosenbaum, Cara Ann ;

McDonnell, Kathryn ;

Waite-Marin, Jessica ;

Berdeja, Jesus G. ;

Raje, Noopur S. ;

Reece, Donna Ellen ;

Vij, Ravi ;

Alonge, Mattina ;

Rosebeck, Shaun ;

Gurbuxani, Sandeep ;

Faham, Malek ;

Kong, Katherine A. ;

Levy, Joan ;

Jakubowiak, Andrzej J. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →